RNasin Plus RNase Inhibitor or Equivalent Tender, USA - 111380742

Procurement Summary

Country : USA

Summary : RNasin Plus RNase Inhibitor or Equivalent

Deadline : 20 Dec 2024

Other Information

Notice Type : Tender

TOT Ref.No.: 111380742

Document Ref. No. : RFQ-75N95025Q00036

Competition : ICB

Financier : Self Financed

Purchaser Ownership : Public

Tender Value : Refer Document

Purchaser's Detail

Name :Login to see tender_details

Address : Login to see tender_details

Email : Login to see tender_details

Login to see details

Tender Details

Description

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued.

(ii) The solicitation number is RFQ-75N95025Q00036 and the solicitation is issued as a request for quotation (RFQ).

This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures; and FAR Part 12—Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold.

(iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) Number 2025-01, with effective date 11/12/2024.

(iv) The associated NAICS code is 334516 and the small business size standard is 1, 000 Employees. This requirement is full and open with no set-aside restrictions.

(v) This requirement is for the following Promega brand name or equal items:

Qty (30) - Item# N261x - RNasin Plus RNase Inhibitor

Salient characteristics:

Ribonuclease Inhibitor must be capable of inhibiting RNase A, B and C as well as human placental RNase.

Ribonuclease Inhibitor must be compatible with use in RNA extractions, RT-PCR, cDNA synthesis, microarrays and in vitro transcription/translation.

Ribonuclease Inhibitor must be compatible with Moloney Murine Leukemia Virus Reverse Transcriptase, or ImProm-II Reverse Transcriptases, Taq and Tfl DNA Polymerases.

Ribonuclease Inhibitor must be compatible with quantitative real-time RT-PCR in a TaqMan Assay.

Ribonuclease Inhibitor must be stable against oxidation and heat for up to 15 minutes at 70 °C.

Ribonuclease Inhibitor must be suitable for long-term storage of samples.

Ribonucleas...
Active Contract Opportunity
Notice ID : RFQ-75N95025Q00036
Related Notice
Department/Ind. Agency : HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-tier : NATIONAL INSTITUTES OF HEALTH
Office: NATIONAL INSTITUTES OF HEALTH NIA
General Information
Contract Opportunity Type: Combined Synopsis/Solicitation (Original)
Original Published Date: Dec 06, 2024 12:39 pm EST
Original Date Offers Due: Dec 20, 2024 04:00 pm EST
Inactive Policy: 15 days after date offers due
Original Inactive Date: Jan 04, 2025
Initiative: None

Classification
Original Set Aside:
Product Service Code: 6640 - LABORATORY EQUIPMENT AND SUPPLIES
NAICS Code: 334516 - Analytical Laboratory Instrument Manufacturing

Place of Performance: Bethesda, MD 20892 USA

Documents

 Tender Notice